Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc

BACKGROUND: Intravaginal rings (IVRs) can deliver antiretroviral (ARV) agents for HIV pre-exposure prophylaxis (PrEP), theoretically overcoming adherence concerns associated with frequent dosing. However, topical vaginal ARV drug delivery has not simultaneously led to sufficient rectal drug exposure...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincent, Kathleen Listiak, Moss, John A., Marzinke, Mark A., Hendrix, Craig W., Anton, Peter A., Gunawardana, Manjula, Dawson, Lauren N., Olive, Trevelyn J., Pyles, Richard B., Baum, Marc M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104940/
https://www.ncbi.nlm.nih.gov/pubmed/30133534
http://dx.doi.org/10.1371/journal.pone.0201952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104940/
https://www.ncbi.nlm.nih.gov/pubmed/30133534
http://dx.doi.org/10.1371/journal.pone.0201952

Ejemplares similares